Research & Development News
Research & Development news
-
News Clinical trial underway for the treatment of traumatic brain injuries
A clinical trial is underway to see if Oxycyte is safer and tolerable in patients with severe non-penetrating traumatic brain injury. -
News Sickle cell disease treatment trial set for 2014
Clinical trials examining the efficacy of a new treatment for sickle cell disease is to begin in 2014. -
News Herpes vaccine clinical trial to start soon
A new clinical trial will discover whether a vaccine for herpes is capable of eradicating the disease. -
News Michigan advocates flu vaccine
Vulnerable people in particular should seek out a flue vaccine this year. -
News FDA approval for cholesterol-lowering injections
A new injectible treatment for cholesterol has been approved by the FDA. -
News Lallemand inaugurates its newest division - Lallemand Health Solutions
Montreal, Canada... Lallemand Inc is pleased to announce the birth of its new division Lallemand Health Solutions. -
News JPT collaborating with IMI to develop diagnostic test for CFS
The two companies wish to identify serological markers to be used as a diagnostic test for CFS. -
News Arthritis 'a serious problem' for the Middle East
Arthroplasty discussion to benefit arthritis sufferers in the UAE. -
News DaVita to provide dialysis in Taiwan
Taipei patients to get dialysis treatment from DaVita. -
News Positive results for myeloma study
Myeloma study approved for phase II after successful phase I. -
News Clinical study affirms efficacy of SIRT with SIR-Spheres microspheres
New clinical research has highlighted the benefits of treating metastatic colorectal cancer with SIR-SPheres microspheres. -
News XenoGesis gets research grant
XenoGesis to research inhalation medicine with view to 'once-a-day' use. -
News PsiOxus to develop biodefence vaccine
Vaccinations to be developed using adjuvants. -
News UK gets oral treatment for NTDT
Thalassaemia patients to get oral treatment. -
News Covidien completes CV Ingenuity acquisition
New acquisition involves revolutionary vascular technology. -
News Dip and Read biosensor to aid drug development
Drug development to be aided by new biosensor -
News Plasma exchange award to encourage research
New grant to encourage plasma transfer research -
News Aspireo Reports Somatoprim Phase I b Interim Data
Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim -
News Ethris Announces Research Based Alliance on SNIM® Modified RNA with Shire
Ethris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. -
News Clinigen Group manages EU patient program
Clinigen Group is managing a patient program for a drug used to treat overexposure to chemotherapy. -
News ADHD extended-release tablets approved by FDA
FDA approval has been granted to new generic ADHD extended-release tablets from Mallinckrodt. -
News Evotec acquires Cell Culture Service GmbH
Evotec has acquired CCS and will integrate its capabilities into existing operations at its Hamburg site. -
News Clinical trial to gauge whether there is a genetic link to severe asthma
A clinical trial is to establish whether there is a genetic link to severe asthma. -
News AstraZeneca in Discovery Pact with Cellular Dynamics
Cellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and tissue cells. -
News Tokyo-based Asklep joins Medidata partner programme to expand clinical trial services
Asklep has joined the Medidata Solutions Partner Programme to increase the quality and efficiency of clinical trials. -
News Study identifies potential new pathway for drug development
A newly found understanding of receptor signaling may have revealed a better way to design drugs. -
News Study paves way to design drugs aimed at multiple protein targets at once
An international research have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once. -
News New screening approach identified potential drug combos for difficult-to-treat melanomas
A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven ... -
News New cell-based system can screen drug candidates for cardiac toxicity
A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process. -
News Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration. -
News Mayo Clinic researchers identify enzyme linked to prostate cancer
Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer. -
News Phenex Enters Into a Research Collaboration and License Agreement with Janssen for Autoimmune and Chronic Inflammatory Disorders
Phenex will receive an upfront payment and is eligible to receive development-related milestones. -
News Industry sponsorship may lead to clinical trial bias
A review has identified industry sponsorship as an important source of bias in clinical trial reports. -
News PerkinElmer launches new assay kits to support biotherapeutic drug development
PerkinElmer has added a range of new assay kits to its product portfolio. -
News PDC Biotech GmbH Announces Successful Clinical Phase I for Its Lead Compound PDC31
PDC Biotech GmbH (PDC) today announced that it has successfully completed a phase I clinical trial for its lead compound for the treatment of preterm labour . -
News AOP Orphan Pharmaceuticals Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)
AOP Orphan announces results from phase II trial in PV at ASH Annual Meeting in Atlanta, U.S.A. Promising efficacy and safety data support further development of AOP2014/P1101 AOP2014/P1101 received Orphan Drug designation in 2011 AOP Orphan is init... -
News Number of sites a key consideration for phase-I clinical trials
A study suggests three or fewer trial sites may be best for phase-I clinical trials. -
News Protagonist and Ironwood expand drug discovery collaboration
The research collaboration between Protagonist and Ironwood is being expanded after making 'remarkable' progress. -
News Sol-Gel Completes Successful Phase II Study in Rosacea
Sol-Gel Technologies Ltd. announced today positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. -
News Sartorius Stedim Biotech Launches Sartoguard NF Prefilter Series
Innovative nanofleece technology provides high flow rates and total throughput performance in combination with excellent clarification capabilities New series concludes the launch of SSB´s Sartoguard range of prefilters -
News Big pharma 'doing more to improve access in developing countries'
GSK, Johnson & Johnson and Sanofi are doing the most to improve access to medicines in developing countries. -
News Partnership leads to new technology for thermostable vaccine production
A novel technology could enable scientists to develop thermostable influenza vaccines. -
News New facility enables ACM Global to offer more clinical trials testing services
ACM Global Central Laboratory's new facility in York, England, doubles its laboratory and office space. -
News Possible new treatment for Ewing sarcoma
Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults. -
News Aptiv Solutions Opens New NC Lab
Aptiv Solutions has opened a new office in Durham, NC in a business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park. -
News Capsugel Opens QC Lab
Capsugel has opened its new quality control lab in Greenwood, SC, doubling its lab capacity and investing more than $3 million. -
News Bend Alliance Develops Thermostable Vax Technology
Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for thermostable vaccine production. -
News Promising drug slows down advance of Parkinson's disease and improves symptoms
Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial. -
News Beactica Extends Fragment-Based Discovery Research Services Agreement
Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development. -
News Cell culture is 'next big pharmaceutical trend'
GBI Research is predicting strong growth in the global cell culture market thanks to increasing demand for biologics and stem cell therapies -
News UK healthcare community seeks to reverse clinical research decline
Industry representatives and policymakers have met to discuss the future of life sciences research and development in the UK. -
News Sihuan Pharmaceutical and NeuroVive to develop cardio-cerebral vascular drugs
Sihuan Pharmaceutical and NeuroVive have announced a collaborative agreement that should help to bring two new cardio-cerebral vascular drugs to market. -
News Affymetrix to collaborate with South African centre on genomics research
A new partnership between Affymetrix and the CPGR in South Africa could ultimately lead to new personalised therapies. -
News TG Therapeutics announces licensing agreement with Ildong
TG Therapeutics and Ildong Pharmaceutical Co have inked a licensing agreement for the development and commercialisation of ublituximab -
News Adaptive clinical trial designs gaining momentum
A report has shed light on pharmaceutical companies' increasing use of adaptive trials. -
News Shire and Boston Children's Hospital enter into broad research collaboration
Shire plc (LSE: SHP, NASDAQ: SHPG) and Boston Children's Hospital today announced a three-year, broad research collaboration in rare diseases. -
News Discovery of molecular pathway of Alzheimer's disease reveals new drug targets
The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be exploited to combat the disease. -
News Drug resistance biomarker could improve cancer treatment
A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell. -
News Study shows large-scale genomic testing feasible, impacts therapy
Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC). -
News TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment. -
News Biotage Universal Phase Separators, Solving an Age Old Problem
Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible... -
News Alzheimers-Immune System Connection Revealed
An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimers disease. -
News Fujifilm Diosynth Biotechnologies Manufactures a New Licensed Biopharmaceutical
Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products. -
News Colby and MannKind announce cancer immunotherapy agreement
Colby and MannKind have revealed details of a new licensing agreement between the two companies. -
News Study confirms validity of data from internet-recruited patients
Quintiles' latest study could pave the way for more direct-to-patient studies using patient-reported outcomes combined with medical record data. -
News New drug significantly lowers bad cholesterol
For many people with high cholesterol, statins serve as the first line of treatment. -
News Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers. -
News Compound in grapes, red wine could be key to fighting prostate cancer
Resveratrol, a compound found commonly in grape skins and red wine, has been shown to have several beneficial effects on human health, including cardiovascular health and stroke prevention. -
News Ensemble and Boehringer Ingelheim to discover macrocycle drug candidates
Ensemble will use its innovative drug discovery platforms to discover and advance drug candidates against Boehringer Ingelheim's drug targets -
News Portola, BMS and Pfizer to collaborate on Eliquis and PRT4445
Portola, BMS and Pfizer aim to find out whether PRT4445 is a safe and effective antidote to Eliquis and other Factor Xa inhibitors. -
News Airgas and Biologics Modular to provide modular facilities for life sciences and pharmaceutical firms
Airgas and Biologics Modular are partnering up to provide a flexible, cost-effective solution to companies and manufacturers that need to expand their life science assets. -
News Researchers at the doorstep of stem cell therapies for MS, other myelin disorders
The potential to replenish populations of cells destroyed by disease was seen by many as the next medical revolution. -
News Insights into a new therapy for a rare form of cystic fibrosis
Scientists have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis. -
News Drug offers new pain management therapy for diabetics
A study shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain. -
News Average drug company spends $237k per medical science liaison
Cutting Edge Information's latest report sheds light on pharmaceutical companies' expenditure on MSL teams. -
News Idera Pharmaceuticals' receptor antagonist performs well in preclinical trials
Idera has published encouraging results from pre-clinical studies involving TLR 7, 8 and 9. -
News Emergent BioSolutions announces Phase 1b study of TRU-016
Phase 1b trials are to get underway to test the efficacy of TRU-016 in treating CLL along with rituximab. -
News Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling
Inhibitors may have utility in autoimmune disease treatment -
News Growing demand for iCAD's Xoft Electronic Brachytherapy System
Demand is growing for the Xoft intraoperative radiation therapy system from iCAD. -
News ImunoGen highlights benefits of T-DM1
ImmunoGen believes its new TAP cancer drug has large potential in the treatment of early stage breast and gastric cancers. -
News Oncologists take 'wait-and-see' approach to biosimilar monoclonal antibodies
US oncologists are taking a cautious approach to prescribing biosimilar versions of monoclonal antibodies. -
News Trials underway for experimental cancer drug pomalidomide
Bone marrow cancer drug posts promising results in clinical trials. -
News GnuBio develops world's first fully integrated DNA sequencer
The world's first fully integrated, commercially available DNA sequencer will be debuted at the Association of Molecular Pathology conference. -
News Most pharma firms now use medical science liaisons to support investigator-initiated trials
A report has explored the growing trend for medical science liaison teams to support investigator-initiated trials. -
News Pharmaron announces drug discovery partnership with AstraZeneca
Pharmaron will provide drug discovery services to pharmaceutical giant AstraZeneca. -
News GSK adopts new transparency policy
GlaxoSmithKline will allow researchers to access detailed clinical trial data upon request. -
News Report spies opportunity for ankylosing spondylitis drug development
Ankylosing spondylitis represents a significantly under-served market, a Frost & Sullivan report says. -
News Future of Pharmaceutical R&D Requires Innovative Dosage Formulations, Industry Survey Shows
Highlights Formulation Knowledge Gap for Challenging Compounds and Outsourcing Priorities -
News UCB opening bio pilot plant in Belgium
A new production facility is being opened by UCB in Belgium to speed up the process of manufacturing cell cultures for clinical trials. -
News Corgenix enjoys growth in contract R&D revenues
Growing contract research and development services helped Corgenix post record revenues for the year ended June 30th. -
News ARIAD presents clinical proof-of-concept for lung cancer drug
ARIAD Pharmaceuticals has published 'compelling' proof-of-concept data for its new tyrosine-kinase inhibitor AP26113. -
News Cabozantinib effective against prostate cancer at lower doses
Cabozantinib is as effective across four key metrics at doses of 40mg a day as it is at doses of 100mg, according to a new study. -
News Promega develops new assay to test cytotoxicity levels
A new assay developed by Promega Corporation is capable of improving cytotoxicity reports from cell cultures gathered within 72 hours. -
News Doctors' perceptions of clinical trials 'influenced by funding sources'
Doctors tend to be biased against industry-funded clinical trials, a study has found. -
News Critical Outcome Technologies Announces Important New Mechanism of Action Data for COTI-2
Critical Outcome Technologies Inc.announced today new data that broadens the mechanism of action (MOA) of the Company's lead oncology asset, COTI-2, beyond AKT inhibition. -
News Critical Outcome Technologies Inc. Initiates Final Toxicity Studies for COTI-2
Critical Outcome Technologies Inc. announced today that it has initiated the final series of toxicity experiments in two animal species for its lead oncology asset, COTI-2. -
News National Human Genome Research Institute Refocuses Extramural Research
The National Institutes of Healths National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine. -
News The Curtain Rises On DNAProtein Interactions
For the first time, scientists have watched proteins interact with long single-stranded DNA molecules in real time.The new method should yield insights into DNA replication and repair, the researchers say. -
News Renewed Focus On Glycoscience
Carbohydrates in molecular biology are like dark matter in the universe, according to sialic acid expert Ajit P. Varki of the University of California, San Diegopoorly studied yet crucial to a full understanding of how things actually work. -
News New data for Novartis drug Lucentis confirms long-term efficacy and safety profile and benefits of individualized treatment
New data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections. -
News Targeting inflammation to treat depression
Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. -
News Lilly Diabetes launches mobile application for whose who support people with type 1 diabetes
Lilly Diabetes announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. -
News Clinical experience with Pradaxa® crosses one million patient-years of treatment
Boehringer Ingelheim has announced that the combined treatment experience with Pradaxa? has crossed one million patient-years(1) in the prevention of thromboembolic events in patients after surgery and in patients with non-valvular atrial fibrillation ... -
News Scottish biotech Aquapharm discovers novel antibiotic compound
Aquapharm Biodiscovery believes the marine-derived compound AQP-182 could help to tackle multi-drug resistant bacteria. -
News Study confirms economic viability of orphan drugs
A new report from Thomson Reuters discusses the economic viability of developing drugs for rare diseases -
News Indian pharma CRAMS sector enjoying 41.4pc growth
India's contract research and manufacturing services sector is due to record 41.4 per cent growth. -
News US industry body attacks BMJ article on pharmaceutical R+D
PhRMA has delivered a robust defence of US pharmaceutical innovation in response to a recent article in the British Medical Journal. -
News Drug Research Innovation Crisis 'Is A Myth'
An analytical article in the BMJ has dismissed claims of an innovation crisis in pharmaceutical R&D. -
News Nodality to Collaborate with Pfizer on Compounds for Autoimmune Disease
Nodality and Pfizer have announced a new collaborative effort to investigate potential compounds for autoimmune disease. -
News Africa The Next Frontier For Novartis Clinical Development
Novartis sees Africa as one of the next frontiers for clinical development. -
News AiCuris Promising Drugs against Herpes Simplex and Human Cytomegalovirus in Preparation for Phase III
AiCuris will present at the International Herpesvirus Workshop in Calgary, Canada, on its two front-running compounds targeting herpes viruses. -
News Covidien Opens R&D Facility in China
Covidien has opened a new $45 million R&D center in Shanghai, China. The center has two core focus areas: design of tailored products and discovery of breakthrough platforms in medical technology. -
News Tokyo-Tech & Astellas Sign Joint Agreement for Drug Discovery Research
Tokyo-Tech and Astellas Pharma are teaming up to identify compounds with anti-protozoan activity. -
News ProMetic & NantPharma to Develop Plasma-derived Biopharmaceuticals
ProMetic has granted NantPro BioSciences rights to its Plasma Protein Purification System and Prion Reduction technologies for the exclusive development and commercialisation of a plasma-derived biopharmaceutical product for the US market. -
News Takeda Resubmits NDAs for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Takeda anticipates that these applications will be reviewed within the next six months. These NDAs were resubmitted in response to the complete response letter Takeda received from the FDA, dated April 25, 2012.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance